Literature DB >> 10090163

Clinical and serological associations of anti-Ku antibody.

H M Cooley1, B J Melny, R Gleeson, T Greco, T W Kay.   

Abstract

OBJECTIVE: To ascertain the clinical and serological associations of anti-Ku antibody.
METHODS: Twenty-seven patients over a 7 year period (1987-1996) had anti-Ku antibody detected by counterimmunoelectrophoresis (CIEP). Nineteen patients were available for clinical review. Five patients were assessed by chart review. Serum was taken at review for repeat antibody analysis. Patients were assigned to diagnostic groups based on the American College of Rheumatology criteria.
RESULTS: There were 22 women and 5 men. The duration of symptoms ranged from one year to 28 years. Nine patients fulfilled criteria for systemic lupus erythematosus (SLE), 4 scleroderma, 3 rheumatoid arthritis (RA), one discoid lupus, and 7 had an undifferentiated connective tissue disease. There was a low incidence of renal (2/24) and central nervous system involvement (1/24); 19/24 had Raynaud's phenomenon, 15/24 had inflammatory arthritis but only one had erosions on radiograph; 11/24 reported esophageal reflux symptoms. Three of 24 patients had myositis. All patients had anti-nuclear antibody using indirect immunofluorescence of > 640 titer with a speckled and nucleolar pattern. Anti-Ku antibody was detected on CIEP in 15/19 sera available for repeat testing. Three patients had anti-Ro antibody, 2 had anti-U1RNP antibody, one patient had anti-topoisomerase-1 and anti-Ro.
CONCLUSION: Anti-Ku antibody is found in a wide variety of connective tissue syndromes. While several patients fulfilled diagnostic criteria for SLE, scleroderma, and RA, their clinical features were usually mild and did not form a distinctive clinical pattern. Common features associated with anti-Ku were Raynaud's phenomenon, arthralgia, skin thickening, and esophageal reflux. Few patients had associated autoantibody specificities found in SLE or scleroderma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090163

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Exposure of HEp-2 cells to stress conditions influences antinuclear antibody reactivity.

Authors:  Liping Du; Sachiko Fukushima; Annahita Sallmyr; Rolf Manthorpe; Anders Bredberg
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies.

Authors:  Adam Maundrell; Susanna Proudman; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-08-05       Impact factor: 2.631

3.  Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations.

Authors:  S Hoa; M Hudson; Y Troyanov; S Proudman; J Walker; W Stevens; M Nikpour; S Assassi; M D Mayes; M Wang; M Baron; M J Fritzler
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort.

Authors:  Katalin Szabó; Levente Bodoki; Melinda Nagy-Vincze; Anett Vincze; Erika Zilahi; Peter Szodoray; Katalin Dankó; Zoltán Griger
Journal:  Biomed Res Int       Date:  2018-10-25       Impact factor: 3.411

5.  The phenotype of myositis patients with anti-Ku autoantibodies.

Authors:  Maria Casal-Dominguez; Iago Pinal-Fernandez; Assia Derfoul; Rose Graf; Harlan Michelle; Jemima Albayda; Eleni Tiniakou; Brittany Adler; Sonye K Danoff; Thomas E Lloyd; Lisa Christoper-Stine; Julie J Paik; Andrew L Mammen
Journal:  Semin Arthritis Rheum       Date:  2021-04-28       Impact factor: 5.431

6.  Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes.

Authors:  Martial Koenig; Marvin J Fritzler; Ira N Targoff; Yves Troyanov; Jean-Luc Senécal
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 7.  Bench to bedside review of myositis autoantibodies.

Authors:  Boaz Palterer; Gianfranco Vitiello; Alessia Carraresi; Maria Grazia Giudizi; Daniele Cammelli; Paola Parronchi
Journal:  Clin Mol Allergy       Date:  2018-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.